Drug Application
Efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis
Xue Yanping, Li Jing, Hou Yunfeng
Published 2020-02-25
Cite as Chin J Pract Med, 2020, 47(4): 100-103. DOI: 10.3760/cma.j.issn.1674-4756.2020.04.031
Abstract
ObjectiveTo analyze the efficacy and safety of rebamipide tablets combined with rabeprazole sodium enteric-coated tablets in the treatment of chronic atrophic gastritis (CAG).
MethodsA total of 192 CAG patients admitted to Central Hospital of Henan Energy Jiaozuo Coal Industry Group from January 2013 to January 2018 were included and randomly divided into control group and observation group according to the ratio of 1∶1, with 96 cases in each group. Control group was treated with rabeprazole sodium enteric-coated tablets, and observation group was given rebamipide tablets + rabeprazole sodium enteric-coated tablets, and they were treated for 4 weeks. The clinical efficacy, pathological scores (gland atrophy, intestinal metaplasia, dysplasia), gastric function-related indicators, including gastrin-17 (GAS-17), pepsinogen I (PGI), epidermal growth factor (EGF), endothelin-1 (ET-1), Hp eradication rate and safety were compared between the two groups.
ResultsAfter treatment, the total improvement rate of treatment and negative conversion rate of Hp in observation group were significantly higher than those in control group, (91.67% and 80.21%) vs. (78.12% and 62.50%), the difference was statistically significant (P<0.05). The scores of gland atrophy, intestinal metaplasia and dysplasia were decreased in the two groups (P<0.05); the scores in observation group were lower than those in control group (P<0.05). The levels of GAS-17 and PGI were increased in the two groups (P<0.05) while the levels of EGF and ET-1 were significantly decreased (P<0.05), and the levels in observation group were superior to those in control group (P<0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05), with good safety.
ConclusionsRebamipide tablets combined with rabeprazole sodium enteric-coated tablets has obvious effects on CAG, and it can effectively alleviate the clinical symptoms of patients and regulate the levels of gastric function-related indicators, with good safety.
Key words:
Rebamipide tablets; Rabeprazole sodium enteric-coated tablets; Chronic atrophic gastritis
Contributor Information
Xue Yanping
Department of Gastroenterology, Central Hospital of Henan Energy Jiaozuo Coal Industry Group, Jiaozuo 454000, China
Li Jing
Department of Gastroenterology, Central Hospital of Henan Energy Jiaozuo Coal Industry Group, Jiaozuo 454000, China
Hou Yunfeng
Department of Gastroenterology, Central Hospital of Henan Energy Jiaozuo Coal Industry Group, Jiaozuo 454000, China
